Chinese

Global Times: China, Cuba eye deepening BRI cooperation

Retrieved on: 
Monday, November 28, 2022

The two leaders witnessed the signing of bilateral documents regarding inter-party exchanges, BRI cooperation and a consultation mechanism between their foreign ministries.

Key Points: 
  • The two leaders witnessed the signing of bilateral documents regarding inter-party exchanges, BRI cooperation and a consultation mechanism between their foreign ministries.
  • Cuba reiterates its firm position of unconditionally abiding by the one-China principle, stressing that Cuba firmly opposes any attempt to use the Taiwan question to interfere in China's internal affairs.
  • They stressed that China-Cuba cooperation and China-Latin America cooperation benefit both sides and do not target any third party.
  • She said improving energy supplies, building power plants and more infrastructure are crucial for Cuba to realize its development goals, and in these fields, China and Cuba could strengthen their win-win cooperation.

Junshi Biosciences Announces Approval of Supplemental Application for Additional Indications of Adalimumab Injection

Retrieved on: 
Tuesday, November 22, 2022

is jointly developed by Junshi Biosciences and Mabwell (Shanghai) Bioscience Co., Ltd.

Key Points: 
  • is jointly developed by Junshi Biosciences and Mabwell (Shanghai) Bioscience Co., Ltd.
  • In March 2022, its indications including rheumatoid arthritis, ankylosing spondylitis and psoriasis were approved by the NMPA.
  • Junshi Biosciences was the first Chinese pharmaceutical company that obtained marketing approval for anti-PD-1 monoclonal antibody in China.
  • Junshi Biosciences has more than 3,100 employees in the United States (San Francisco and Maryland) and China (Shanghai, Suzhou, Beijing and Guangzhou).

TRACON Pharmaceuticals Announces Dosing of First Patient in Phase 1/2 Trial of YH001 in Combination with Envafolimab and Doxorubicin in Front Line Sarcoma

Retrieved on: 
Monday, November 21, 2022

The Phase 1/2 trial will assess the safety and efficacy of the triplet combination of YH001, envafolimab and doxorubicin in the common sarcoma subtypes of leiomyosarcoma and dedifferentiated liposarcoma.

Key Points: 
  • The Phase 1/2 trial will assess the safety and efficacy of the triplet combination of YH001, envafolimab and doxorubicin in the common sarcoma subtypes of leiomyosarcoma and dedifferentiated liposarcoma.
  • Dosing the first patient in a trial that studies envafolimab with YH001 in front line sarcoma patients, including in combination with standard of care doxorubicin, is an important step to inform us as to the subtypes of sarcoma which should enroll in the front line Phase 3 trial.
  • For more information on the Phase 1/2 trial of YH001 in combination with envafolimab and doxorubicin in advanced or metastatic sarcoma, please visit ClinicalTrials.gov and reference Identifier NCT05448820 .
  • The primary objective of the Phase 1 portion of the trial is to determine the recommended phase 2 dose ofYH001in combination with envafolimab and in combination with envafolimab with doxorubicin.

United States Liquid Biopsy Market Report 2022: Industry Trends, Growth, Outlook, Impact of COVID-19, Company Analysis 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, November 25, 2022

The "United States Liquid Biopsy Market, Size, Global Forecast 2022-2027, Industry Trends, Growth, Outlook, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "United States Liquid Biopsy Market, Size, Global Forecast 2022-2027, Industry Trends, Growth, Outlook, Impact of COVID-19, Company Analysis" report has been added to ResearchAndMarkets.com's offering.
  • However, the reduced sensitivity of some liquid biopsies may limit market growth in the United States throughout the foreseeable period.
  • The liquid biopsy market in the United States is split into four categories: lung cancer, breast cancer, colorectal cancer, and prostate cancer.
  • The liquid biopsy market in the United States is classified into three categories: kits and consumables, instruments, and services.

Global NEV Sales Reached 2.87 Million Units for 3Q22 as BYD Trailed Closely Behind Tesla in BEV Segment, Says TrendForce

Retrieved on: 
Thursday, November 24, 2022

Of the quarterly total, BEV sales accounted for 2.147 million units and registered a YoY growth of 75%, whereas PHEV sales accounted for 714,000 units and registered a YoY growth of 57%.

Key Points: 
  • Of the quarterly total, BEV sales accounted for 2.147 million units and registered a YoY growth of 75%, whereas PHEV sales accounted for 714,000 units and registered a YoY growth of 57%.
  • In the global ranking of BEV brands by vehicle sales for 3Q22, Tesla took first place with 344,000 units.
  • While Tesla managed to maintain its market share at 16%, its lead over second-placed BYD in sales figure had narrowed further.
  • It is also worth noting that the gap between Tesla and BYD in BEV sales has been smaller than 100,000 units for two quarters straight.

LSI Announces First Ever Medtech Ecosystem Partner in China

Retrieved on: 
Thursday, November 17, 2022

Together, Mednovation and LSI will foster innovation and expand support for medtech leaders in the Chinese ecosystem.

Key Points: 
  • Together, Mednovation and LSI will foster innovation and expand support for medtech leaders in the Chinese ecosystem.
  • View the full release here: https://www.businesswire.com/news/home/20221117005006/en/
    As LSIs preferred partner in China, Mednovation will support LSI events, market intelligence products, research services, and other strategic initiatives in China.
  • We are thrilled to join forces with LSI and become their preferred partner in China, said William Jin, Partner at Mednovation.
  • LSIs Emerging Medtech Summits (LSI USA and LSI Europe) bring innovators, investors, strategics, and service providers together at world-class venues to facilitate personalized partnering.

China Buy Now Pay Later (BNPL) Business Report 2022: Payments are Expected to Grow by 37.2% to Reach $119,251.4 Million by the End of 2022 - Forecasts to 2028 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 15, 2022

BNPL payments are expected to grow by 37.2% on an annual basis to reach US$119,251.4 million in 2022.

Key Points: 
  • BNPL payments are expected to grow by 37.2% on an annual basis to reach US$119,251.4 million in 2022.
  • BNPL payment adoption is expected to grow steadily over the forecast period, recording a CAGR of 19.9% during 2022-2028.
  • The BNPL Gross Merchandise Value in the country will increase from US$86,905.0 million in 2021 to reach US$353,898.4 million by 2028.
  • In China, buy now pay later (BNPL) is gaining rapid momentum even in the face of a softer macro landscape.

Jointly Released by Tricor and JunHe, 'Foreign Private Equity Funds in China - Guide to Market Entry and Operations 2022' Provides an Introduction to PE funds in China

Retrieved on: 
Thursday, November 24, 2022

Our purpose is to interpret the development of foreign PE funds and relevant regulatory provisions in China, and provide suggestions for establishment and operations.

Key Points: 
  • Our purpose is to interpret the development of foreign PE funds and relevant regulatory provisions in China, and provide suggestions for establishment and operations.
  • In terms of the number of managers and the scale of funds, PE investment funds play an important role.
  • As of the first half of the 2022, the number of foreign PE funds totaled 801, including 259 JVs.
  • The target amount of funds totaled USD 313.95 billion, and the target amount of JV PE funds totaled USD 83.07 billion.

Xinhua Silk Road: Economic development, financial cooperation amid changes highlighted at Financial Street Forum 2022 annual conference

Retrieved on: 
Wednesday, November 23, 2022

BEIJING, Nov. 23, 2022 /PRNewswire/ --The Annual Conference of Financial Street Forum 2022 kicked off in Beijing on Monday with the theme "Forge Ahead Toward a Shared Future: Economic Development and Financial Cooperation Amid Changes", attracted participants shared their views and insights regarding the conference theme.

Key Points: 
  • BEIJING, Nov. 23, 2022 /PRNewswire/ --The Annual Conference of Financial Street Forum 2022 kicked off in Beijing on Monday with the theme "Forge Ahead Toward a Shared Future: Economic Development and Financial Cooperation Amid Changes", attracted participants shared their views and insights regarding the conference theme.
  • Yin Li, secretary of the Communist Party of China (CPC) Beijing Municipal Committee, said at the conference that, Beijing will continue to strengthen the development of the financial sector to inject impetus into the real economy, at the same time, Beijing is committed to deepening reform and innovation in the financial sector to promote a higher level of financial opening-up.
  • Fu Hua, president of Xinhua News Agency, said that Xinhua will be firmly committed to strengthening news coverage and relevant information services in China's financial sector to provide strong support for the healthy development of China's financial industry.
  • This year's forum is jointly organized by the People's Government of Beijing Municipality, the People's Bank of China, Xinhua News Agency, China Banking and Insurance Regulatory Commission, China Securities Regulatory Commission and the State Administration of Foreign Exchange.

Xinhua Silk Road: Economic development, financial cooperation amid changes highlighted at Financial Street Forum 2022 annual conference

Retrieved on: 
Wednesday, November 23, 2022

BEIJING, Nov. 22, 2022 /PRNewswire/ --The Annual Conference of Financial Street Forum 2022 kicked off in Beijing on Monday with the theme "Forge Ahead Toward a Shared Future: Economic Development and Financial Cooperation Amid Changes", attracted participants shared their views and insights regarding the conference theme.

Key Points: 
  • BEIJING, Nov. 22, 2022 /PRNewswire/ --The Annual Conference of Financial Street Forum 2022 kicked off in Beijing on Monday with the theme "Forge Ahead Toward a Shared Future: Economic Development and Financial Cooperation Amid Changes", attracted participants shared their views and insights regarding the conference theme.
  • Fu Hua, president of Xinhua News Agency, said that Xinhua will be firmly committed to strengthening news coverage and relevant information services in China's financial sector to provide strong support for the healthy development of China's financial industry.
  • This year's forum is jointly organized by the People's Government of Beijing Municipality, the People's Bank of China, Xinhua News Agency, China Banking and Insurance Regulatory Commission, China Securities Regulatory Commission and the State Administration of Foreign Exchange.
  • View original content to download multimedia: https://www.prnewswire.com/news-releases/xinhua-silk-road-economic-devel...